// EFFECTIVE UNTIL SEPTEMBER 30, 2023 PER CHAPTER 532 OF 2019 //
(a) Beginning January 1, 2020, the Department shall establish a medication–assisted treatment program that utilizes at least one formulation of each FDA–approved full opioid agonist, partial opioid agonist, and long–acting opioid antagonists used for the treatment of opioid use disorders in the Baltimore Pre–trial Complex.
(b) Funding for the program shall be as provided in the State budget.
(c) The Department shall, in consultation with its head of medical treatment services, determine whether the program is capable of being administered in existing structures of the Baltimore Pre–trial Complex.